medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2022, Number 2

<< Back

Medicina & Laboratorio 2022; 26 (2)

New-onset refractory status epilepticus (NORSE): case report

Rosero-Arellano C

Language: Spanish
References: 17
Page: 187-1997
PDF size: 579.41 Kb.


ABSTRACT

New-onset refractory status epilepticus (NORSE) is a neurological emergency with high morbidity and mortality, that results in elevated costs due to its complex therapeutic management and the requirement for a rapid and sequential evaluation. It is a condition with a poor prognosis and its main etiology is autoimmune encephalitis. However, it is difficult to diagnose and sometimes a clear cause cannot be established. The case of a young female with no relevant medical history is described. She presented multiple seizure episodes refractory to anticonvulsants and deep sedation, without tolerating withdrawal of sedoanalgesia due to reappearance of seizures in the electroencephalogram. She presented studies of cerebrospinal fluid, infections, neuroimaging and autoimmunity without alterations. She had healthcare-associated pneumonia, which progressed to multiple organ dysfunction and death. No post-mortem anatomopathological alterations were found to explain the cause of the status epilepticus. New-onset refractory status epilepticus is a condition that represents both a diagnostic and therapeutic challenge. Its diagnostic approach and treatment options are described, as well as a brief review of the available literature.


REFERENCES

  1. Mantoan-Ritter L, Nashef L. New-onset refractorystatus epilepticus (NORSE). Pract Neurol 2021;21:119-1271. https://doi.org/10.1136/practneurol-2020-002534.

  2. Wilder-Smith EP, Lim EC, Teoh HL, SharmaVK, Tan JJ, Chan BP, et al. The NORSE (newonsetrefractory status epilepticus) syndrome:defining a disease entity. Ann Acad Med Singap2005;34:417-420.

  3. Gofton TE, Gaspard N, Hocker SE,Loddenkemper T, Hirsch LJ. New onset refractorystatus epilepticus research: What is on thehorizon? Neurology 2019;92:802-810. https://doi.org/10.1212/wnl.0000000000007322.

  4. Périn B, Szurhaj W. New onset refractory statusepilepticus: State of the art. Rev Neurol (Paris)2022;Jan 11:S0035-3787(0021)00791-00798.https://doi.org/10.1016/j.neurol.2021.12.005.

  5. Lattanzi S, Leitinger M, Rocchi C, SalveminiS, Matricardi S, Brigo F, et al. Unraveling theenigma of new-onset refractory status epilepticus:a systematic review of aetiologies.Eur J Neurol 2022;29:626-647. https://doi.org/10.1111/ene.15149.

  6. Gaspard N, Hirsch LJ, Sculier C, LoddenkemperT, van Baalen A, Lancrenon J, et al. Newonsetrefractory status epilepticus (NORSE) andfebrile infection-related epilepsy syndrome (FIRES):State of the art and perspectives. Epilepsia2018;59:745-752. https://doi.org/10.1111/epi.14022.

  7. Santamarina E, Abraira L, Toledo M. Actualizaciónen el estado de mal epiléptico (statusepilepticus). Med Clin 2019;153:70-77. https://doi.org/10.1016/j.medcli.2019.01.013.

  8. Costello DJ, Kilbride RD, Cole AJ. Cryptogenicnew onset refractory status epilepticus(NORSE) in adults-Infectious or not? J NeurolSci 2009;277:26-31. https://doi.org/10.1016/j.jns.2008.10.007.

  9. Gaspard N, Foreman BP, Alvarez V, CabreraKang C, Probasco JC, Jongeling AC, et al.New-onset refractory status epilepticus: Etiology,clinical features, and outcome. Neurology2015;85:1604-1613. https://doi.org/10.1212/wnl.0000000000001940.

  10. Meletti S, Giovannini G, d'Orsi G, Toran L,Monti G, Guha R, et al. New-onset refractorystatus epilepticus with claustrum damage:Definition of the clinical and neuroimagingfeatures. Front Neurol 2017;8:111. https://doi.org/10.3389/fneur.2017.00111.

  11. Sculier C, Gaspard N. New onset refractorystatus epilepticus (NORSE). Seizure2019;68:72-78. https://doi.org/10.1016/j.seizure.2018.09.018.

  12. Bhatia K, De Jesus O. New onset refractorystatus epilepticus. StatPearls. Treasure Island(FL): StatPearls Publishing; 2021. Acceso 08 deagosto de 2021. Disponible en https://www.ncbi.nlm.nih.gov/books/NBK567765/.

  13. Hon KL, Leung AKC, Torres AR. Febrile infection-related epilepsy syndrome (FIRES):An overview of treatment and recent patents.Recent Pat Inflamm Allergy Drug Discov2018;12:128-135. https://doi.org/10.2174/1872213x12666180508122450.

  14. Suchdev K, Kupsky WJ, Mittal S, Shah AK.Histopathology of new-onset refractory statusepilepticus (NORSE) in adults. Seizure2021;93:95-101. https://doi.org/10.1016/j.seizure.2021.09.018.

  15. Yanagida A, Kanazawa N, Kaneko J, KanekoA, Iwase R, Suga H, et al. Clinically based scorepredicting cryptogenic NORSE at the earlystage of status epilepticus. Neurol NeuroimmunolNeuroinflamm 2020;7:e849. https://doi.org/10.1212/NXI.0000000000000849.

  16. Zeiler FA, Zeiler KJ, Teitelbaum J, GillmanLM, West M. Modern inhalational anestheticsfor refractory status epilepticus. Can J NeurolSci 2015;42:106-115. https://doi.org/10.1017/cjn.2014.121.

  17. Sakuma H, Horino A, Kuki I. Neurocriticalcare and target immunotherapy for febrileinfection-related epilepsy syndrome. BiomedJ 2020;43:205-210. https://doi.org/10.1016/j.bj.2020.03.009.




2020     |     www.medigraphic.com